Medindia

X

Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results

Wednesday, May 11, 2011 General News J E 4
Advertisement

Valeant Pharmaceuticals International

Pro Forma Organic Growth - by Segment

For the Three Months Ended March 31, 2011

(In thousands)

Three Months Ended

March 31,

Mar YTD2011

Pro formaMar YTD2010 (c)

%   Change

Mar YTD  2011 currency impact

Mar YTD excluding currency impact

%Change

Mar YTDacquisitionimpact at2010 rates

Mar YTDexcludingcurrency &acquisitionimpact

Mar YTDgrowth atconstantcurrency,net ofacquisitions

Product Sales (a)(b)

 U.S. Dermatology

$   95,919

$   73,418

31%

$       (25)

$   95,894

31%

$      (6,531)

$     89,363

22%

 U.S. Neurology & Other

203,544

189,713

7%

-

203,544

7%

(20,625)

182,919

-4%

Total U.S.

299,463

263,131

14%

(25)

299,438

14%

(27,156)

272,282

3%

Canada/Australia

69,050

58,778

17%

(4,415)

64,635

10%

(3,843)

60,792

3%

Specialty pharmaceuticals

368,513

321,909

14%

(4,440)

364,073

13%

(30,999)

333,074

3%

Branded generics - Latin America

56,383

42,058

34%

(3,260)

53,123

26%

(6,471)

46,652

11%

Branded generics - Europe

75,525

49,551

52%

(98)

75,427

52%

(17,042)

58,385

18%

Branded Generics

131,908

91,609

44%

(3,358)

128,550

40%

(23,513)

105,037

15%

Total product sales

500,421

413,518

21%

(7,798)

492,623

19%

(54,512)

438,111

6%

Royalties

20,740

17,041

22%

-

20,740

22%

-

20,740

22%

Total organic revenue

$ 521,161

$ 430,559

21%

$  (7,798)

$ 513,363

19%

$    (54,512)

$   458,851

7%

Organic Growth - excluding Diastat & Efudex

Diastat adjustment

$   (7,914)

$ (15,864)

-50%

$         -

$   (7,914)

-50%

$             -

$      (7,914)

-50%

 U.S. Neurology & Other

195,630

173,849

13%

-

195,630

13%

(20,625)

175,005

1%

Efudex adjustment

(1,630)

(10,307)

-84%

-

(1,630)

-84%

-

(1,630)

-84%

 U.S. Dermatology

94,289

63,111

49%

(25)

94,264

49%

(6,531)

87,733

39%

Total product sales

$ 490,877

$ 387,347

27%

$  (7,798)

$ 483,079

25%

$    (54,512)

$   428,567

11%

Total organic revenue

$ 511,617

$ 404,388

27%

$  (7,798)

$ 503,819

25%

$    (54,512)

$   449,307

11%

(a) See footnote (a) to Table 3.

(b) See footnote (b) to Table 2.

(c) Combined Legacy Biovail and Legacy Valeant product sales and royalty.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PHC Secures Rate Increase from Existing Contract w...
S
ADVENTRX Reports First Quarter 2011 Financial Resu...